National Comprehensive Cancer Network guidelines do not recommend routine genetic testing for women > 65 with newly diagnosed breast cancer. We performed a retrospective review of data from the Legacy Cancer Institute Tumor Registry of women with a new diagnosis of breast cancer between January 2017 and December 2022. Primary endpoint was the incidence of deleterious mutation. 4548 women with a diagnosis of breast cancer were identified. 2059/4548 (45.3%) were older than 65 at the time of diagnosis.
